VICENTE
ESTRADA PÉREZ
Profesor titular de universidad
![Foto de Esteban](/img/nophoto.png)
Esteban
Ribera Pascuet
Publicaciones en las que colabora con Esteban Ribera Pascuet (16)
2022
-
Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort
HIV Medicine, Vol. 23, Núm. 8, pp. 825-836
2021
-
COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study
HIV Medicine, Vol. 22, Núm. 9, pp. 867-876
-
Late presentation for HIV impairs immunological but not virological response to antiretroviral treatment
AIDS (London, England), Vol. 35, Núm. 8, pp. 1283-1293
-
Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIV
PloS one, Vol. 16, Núm. 4, pp. e0249515
2020
-
How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain
HIV Medicine, Vol. 21, Núm. 2, pp. 128-134
2019
-
Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018)
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 3, pp. 195-202
2017
-
Very low level viraemia and risk of virological failure in treated HIV-1-infected patients
HIV Medicine, Vol. 18, Núm. 3, pp. 196-203
2016
-
Executive summary: Prevención y tratamiento de infecciones oportunistas y otras coinfecciones en pacientes infectados por el VIH: mayo de 2015
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 34, Núm. 8, pp. 517-523
-
Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013
Journal of Infection, Vol. 72, Núm. 5, pp. 587-596
-
Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 34, Núm. 8, pp. 516.e1-516.e18
2015
-
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): A randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 785-792
-
Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015)
Enfermedades infecciosas y microbiologia clinica
-
Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio
HIV Medicine, Vol. 16, Núm. 6, pp. 370-374
2013
-
Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: The RECOMB study
HIV Medicine, Vol. 14, Núm. 6, pp. 327-336
2012
-
Switching to raltegravir in virologically suppressed in HIV-1-infected patients: A retrospective, multicenter, descriptive study
Current HIV Research, Vol. 10, Núm. 8, pp. 673-678